Kura Oncology names Jennifer Fulk as chief financial officer
Fulk takes over principal financial and accounting officer duties effective September 8, 2026, under an employment agreement with severance terms tied to a change of control.
SEC filing
Latest
3 stories
Tuesday, September 8
Wednesday, August 12
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026
The company reported majority share of new patient starts in its menin inhibitor class and $519 million in cash to fund the ziftomenib program toward 2028 Phase 3 results.
SEC filing
Wednesday, July 29
Kura Oncology updates severance terms for CEO and two other executives
The company revised employment agreements for Troy Wilson, Brian Powl, and Kathleen Ford, changing certain severance provisions tied to termination and change-in-control scenarios.
SEC filing